For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Phathom Pharmaceuticals, Inc. (PHAT) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-07): Designation Low · Gem Score -17 (−100…+100 Quality+Value blend) · Quality 3 · Value -33 · Sentiment -21 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Phathom Pharmaceuticals, Inc.
PHAT NASDAQPhathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s commercial portfolio centers on vonoprazan-based therapies, including VOQUEZNA for the relief of heartburn associated with non-erosive and erosive GERD and the healing and maintenance of erosive GERD in adults. It also markets VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK for the treatment of Helicobacter pylori infection in adults. Phathom Pharmaceuticals operates as a specialist in acid-related GI disorders, combining research, product development, and commercialization to address conditions that affect the digestive system.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics TTM · through Jun 30, 2026
EPS (Diluted): -1.24
Total Equity: -$344.27M
Shares: 79,731,386
Total Debt: $164.59M
Cash: $182.48M
EBITDA: -$40.13M
Total Debt: $164.59M
Cash: $182.48M
Revenue: $239.66M
Shares: 79,731,386
Revenue: $239.66M
Revenue: $239.66M
Revenue: $239.66M
Total Equity: -$344.27M
Tax Rate: N/A
Equity: -$344.27M
Total Debt: $164.59M
Cash: $182.48M
Current Liabilities: $153.78M
Long-Term Debt: $164.59M
Total Debt: $164.59M
Total Equity: -$344.27M
Shares: 79,731,386
Shares: 79,731,386
CapEx: -$219,000
Shares: 79,731,386
Stock Price: $7.74
Net Income: -$99.07M
Industry Benchmarks
Income Statement (Annual)
Last updated: Sep 11, 2026 10:56am (26d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $682,000 | $55.3M | $175.1M |
| Cost of Revenue | — | $0 | $167,000 | $8.0M | $22.6M |
| Gross Profit | — | $0 | $515,000 | $47.3M | $152.5M |
| Operating Expenses | $135.1M | $172.4M | $167.8M | $324.7M | $312.5M |
| Operating Income | -$135.1M | -$172.4M | -$167.3M | -$277.5M | -$160.0M |
| Net Income | -$143.9M | -$197.7M | -$201.6M | -$334.3M | -$221.2M |
| EBITDA | -$134.6M | -$171.8M | -$166.7M | -$276.7M | -$159.4M |
| EPS | $-1.78 | $-2.44 | $-2.49 | $-5.29 | $-3.03 |
| EPS (Diluted) | $-1.78 | $-2.44 | $-2.49 | $-5.29 | $-3.03 |
Balance Sheet (Annual)
Last updated: Sep 11, 2026 10:56am (26d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $183.3M | $155.4M | $381.4M | $297.3M | $130.0M |
| Total Current Assets | $186.5M | $160.5M | $397.4M | $360.1M | $229.0M |
| Total Assets | $189.4M | $164.8M | $413.8M | $378.3M | $259.1M |
| Current Liabilities | $18.9M | $26.2M | $38.8M | $85.7M | $132.0M |
| Long-Term Debt | $89.7M | $95.3M | $137.8M | $201.4M | $209.1M |
| Total Liabilities | $117.3M | $239.6M | $486.6M | $631.9M | $697.3M |
| Total Equity | $72.2M | -$74.8M | -$72.8M | -$253.6M | -$438.2M |
| Retained Earnings | -$529.4M | -$727.1M | -$928.7M | -$1.3B | -$1.5B |
Cash Flow (Annual)
Last updated: Sep 11, 2026 10:56am (26d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$148.6M | -$146.5M | -$137.6M | -$266.8M | -$166.8M |
| Capital Expenditure | $-328,000 | -$1.0M | -$1.6M | $-135,000 | $-229,000 |
| Free Cash Flow | -$148.9M | -$147.6M | -$139.2M | -$266.9M | -$167.0M |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | $42.8M | $0 | $39.3M | $59.4M | $0 |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | -$104.2M | -$27.5M | $228.4M | -$84.1M | -$167.3M |
Growth Trends (YoY %)
Last updated: Sep 11, 2026 10:56am (26d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | +8,001.5% | +216.9% |
| Gross Profit Growth | — | — | +9,080.4% | +222.6% |
| Operating Income Growth | -27.7% | +3.0% | -65.8% | +42.3% |
| Net Income Growth | -37.4% | -2.0% | -65.8% | +33.8% |
| EBITDA Growth | -27.7% | +3.0% | -65.9% | +42.4% |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Not computed yetNarrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-09-17 17:19The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Independent read on the tape first: quarterly revenue has gone $16.4M → $28.5M → $29.7M → $39.5M → $49.5M → $57.6M → $58.3M → $74.3M. That's not decelerating — the June 2026 quarter is a 27% sequential jump and 88% YoY, the biggest sequential print in the series. The "quarterly trend: decelerating" tag in Revenue Confidence looks wrong, or is measuring second-derivative on a smoothed basis; either way it's misleading. More importantly, net loss narrowed from -$75.8M in Q2 2025 to -$17.6M in Q2 2026 while revenue nearly doubled — that's operating leverage showing up in real time. TTM revenue is roughly $240M (sum of last four quarters), not the $175M annual figure the synthesis keeps anchoring to. At $0.63B market cap that's EV/sales closer to 2.0x on a run-rate basis, and Q2 alone annualizes to ~$297M.
The bear case that matters is the balance sheet, not the commercial story. $130M cash against $167M annual burn in 2025 = runway measured in quarters, not years, and equity is already -$438M with $209M debt. But the burn trajectory is collapsing: Q2 2026 net loss of $17.6M annualizes to ~$70M, less than half of 2025's cash burn. If gross margin stays at 83% and opex holds roughly flat, this company hits operating breakeven somewhere in the next 2-4 quarters. That completely changes the dilution math — a single $75-100M raise (12-15% dilution at current price) probably bridges to self-funding, versus the "multiple rounds of dilutive financing" the pre-flight assumes. The synthesis and market-forces models are both anchored on stale 2025 annual numbers and miss that the Q2 2026 print materially de-risks the financing crisis.
Where I push back on the models: thesis-eval scores this -7 with the "generic PPI wall" as a 72-weight bear. That wall exists but is being empirically breached — you cannot grow prescriptions 4.5x in eight quarters against generics if the wall is impermeable. The narrative layer calls it "unanchored/turnaround-bet" but the trajectory is now anchoring: run-rate revenue times a reasonable specialty-pharma 4-5x sales at profitability = $1.2-1.5B EV, roughly 2x current. Contrarian counter: insider activity is all awards and F-inkind tax withholding — zero open-market buying at $7.74 near 52-week lows, which is a real tell when management should know if the Q3 script data supports continuation. The gift transaction (28,000 shares) is also mildly negative signal. And the -$438M equity with $209M debt means any covenant trip or refi at bad terms wipes equity holders — this is a genuinely leveraged bet on continued execution.
Data-quality flags: the ev_to_ebitda TTM vs annual gap (237%) confirms fundamentals are moving fast enough that any static multiple is stale within a quarter. The momentum module's 391% revenue CAGR is arithmetic noise off a near-zero 2023 base — useless. Real number is 88% YoY in the most recent quarter, still exceptional. Synthesis's "high conviction required" verdict is the right posture but it under-weights how much the Q2 print changed the runway math. Market-forces "neutral" feels lazy given the setup: this is a binary that has moved measurably toward the bull side in the last two prints while the stock sits at 52-week lows. My read: the stock is priced for a financing crisis that the June quarter partially defused. Fair value on run-rate revenue and a credible path to breakeven in 2026 is $12-14; downside on a bad Q3 and forced raise is $4-5. Asymmetry is favorable but not overwhelming given the negative equity. Small position warranted; not table-pounding because insiders aren't buying and one bad script-trend quarter breaks the thesis.
GPT Reading
What jumps out first is that the business is actually moving from biotech hope to specialty-pharma operating company faster than the stock price implies. TTM revenue through 2026-06-30 is about $240 million, up from roughly $114 million in the prior TTM, so growth is still a bit above 100% even off a much larger base. More importantly, the quarterly trajectory remains intact: revenue went from $16.4 million in 2024-09 to $29.7 million, $28.5 million, $39.5 million, then $49.5 million, $57.6 million, $58.3 million, and now $74.3 million. That is not a launch rolling over; it is a product finding a market. Gross margin at 82.9% is exactly what you want in a drug franchise, and losses are narrowing sharply as scale builds. Net loss improved from -$85.6 million two years ago to -$17.6 million in the latest quarter, while operating margin on a TTM basis has tightened to -17.0%. At an enterprise value of only about 2.3x TTM revenue and a market cap of $630 million, the market is still valuing this like a fragile concept, not a commercial asset with visible operating leverage.
The second thing the numbers say is that the cash-burn panic is increasingly stale if the current run-rate holds. The annual 2025 operating cash outflow of -$166.8 million and free cash flow of -$167.0 million look ugly, but they are backward-looking and describe a year when quarterly revenue averaged only $43.8 million. The latest quarter lost just $17.6 million on $74.3 million of sales, versus a loss of $75.8 million on $39.5 million a year earlier. That is a huge incremental margin improvement. If quarterly revenue has crossed into the $70 million-plus zone, the path to breakeven is no longer heroic; it looks plausibly within reach with another year of execution. Yes, the balance sheet is imperfect, with $130.0 million of cash versus $209.1 million of debt and negative equity of $438.2 million, but negative equity is not the key issue here. The real question is whether the business needs another dilutive raise before it becomes self-funding. Based on the earnings trend, I think the probability of a near-term financing spiral is materially lower than the stock suggests.
That is why I come out constructive here. At $7.74, investors are paying about 2.6x sales for a company whose most recent quarter grew 88% year over year and 27% sequentially, with losses compressing fast. For a one-product biotech that would be expensive if revenue quality were suspect, but these numbers look like authentic launch scaling. The market seems anchored to two old facts—that GERD is crowded and that Phathom historically burned cash—while underweighting the newer fact that commercialization is working. This is not a clean, high-certainty compounder, but if the company can sustain even mid-teens sequential growth for a few more quarters, annualized revenue gets into a range where this equity should not trade like a distressed option. I think fair value is higher, closer to $11-13, which still does not assume perfection.
The best case against that view is obvious and serious: this is still a single-franchise story competing against cheap generics in a category where physician inertia is real. TTM net margin is still -41.3%, annual free cash burn was still -$167 million, and the company ended the last annual period with only $130 million of cash against $209 million of debt. If launch momentum softens even modestly, the apparent operating leverage can disappear because SG&A and market access costs stay high while the balance sheet forces management back to the capital markets. There is also a subtle warning in the quarterly revenue cadence: $57.6 million to $58.3 million looked flat before the jump to $74.3 million, so one strong quarter does not prove a straight-line trend. A skeptic can also reasonably say that 2.3x EV/revenue is not obviously cheap for a company that remains unprofitable, leveraged, and dependent on one commercial asset in a brutally competitive market. I weigh those points differently because the latest quarter was strong enough to reset the trajectory, but they are the reason this is not a high-conviction table-pound.
What would change my mind is straightforward. If the next two quarters show revenue slipping back into the $55-60 million range, or if net losses re-expand above roughly $30 million per quarter, then the “self-funding soon” thesis is wrong and the financing overhang should dominate. Likewise, any evidence that operating cash burn is not converging materially from the -$166.8 million annual pace would make the balance sheet the main story again. On the other hand, if quarterly revenue stays above $70 million and losses continue narrowing toward breakeven, the stock should rerate quickly because the current valuation still embeds too much skepticism about whether this launch is real.
Grok Reading
Phathom at $7.74 and a $0.63B market cap is a commercial launch that the market has already marked down as a likely financing casualty, and the raw trajectory does not fully support that discount. Trailing twelve-month revenue through mid-2026 is roughly $240M (Q2’26 $74.3M + Q1 $58.3M + Q4’25 $57.6M + Q3’25 $49.5M), up from $175M for calendar 2025 and only $55M in 2024. Sequential growth stalled in Q1’26 (+1% QoQ) then reaccelerated hard in Q2 (+27% QoQ to $74.3M), putting recent year-over-year growth near 88% versus the year-ago $39.5M quarter. Gross margin holds at 83%, so incremental revenue is high-quality; the more important signal is the loss curve: net income improved from –$75.8M in Q2’25 to –$17.6M in Q2’26, and TTM net losses have compressed to roughly –$99M versus the –$221M full-year 2025 print. Operating margin TTM is already only –17%. At 2.6× trailing sales and ~2.3× EV/revenue, the equity is pricing a high probability that this ramp dies or that dilutive capital permanently caps upside—neither of which is yet visible in the quarterly P&L.
The balance sheet is the genuine constraint, not the product. Year-end 2025 cash of $130M against $209M of debt and –$438M of equity, with 2025 free-cash-flow burn of –$167M, means the company still needs the loss trajectory to keep collapsing or it will raise equity into a weak tape. Current ratio near 1.9 buys some time, and if Q2’26’s –$18M net loss run-rate continues to improve with volume, annual cash burn could fall inside $50–80M and stretch the runway past the next couple of years of VOQUEZNA adoption. That is a narrow path, not a comfortable one, and it is why the stock sits near the $7.59 fifty-two-week low after a 58% drawdown. Still, a single commercial product growing through $240M TTM with 83% gross margins and visibly shrinking losses is not a pre-revenue binary; it is an execution story the market is treating like a distressed biotech.
The strongest counter-argument is straightforward: VOQUEZNA must fight a permanent wall of cheap generic PPIs, Q1’26 already showed a sequential stall that the “decelerating revenue confidence” flag correctly flagged, and the company has never generated positive operating cash flow. Negative equity plus $209M of debt means any stumble forces dilution at prices that permanently impair the equity story the bulls need. Insider prints are awards, gifts, and option mechanics—no open-market buying that would signal conviction from people who see the scripts. If the generic-PPI share floor is lower than management models, or if primary-care uptake never broadens beyond the gastroenterology early adopters, revenue asymptotes well below the $400M level required for clean profitability and the current 2.6× sales multiple becomes a value trap rather than a cheap option. Those risks are real and explain why prior models scored the thesis slightly negative and called market forces neutral-to-hostile.
I weigh the improving unit economics and the Q2 reacceleration more heavily than the financing scare because the loss compression is already large and the product is generating real cash gross profit at scale; dilution risk is binary and priced, while the commercial ramp is observable every quarter. What would flip me is two consecutive quarters of flat-to-down sequential revenue, a capital raise below $6, or operating cash burn that fails to improve below a $100M annual run-rate while cash drops under $80M. Conversely, a clean quarter above $85–90M revenue with net loss inside $10M, or any non-dilutive refinancing that pushes net debt down, would make the undervaluation case table-pounding rather than moderate.
Qwen Reading local experiment · off-panel
The most glaring contradiction in this dataset is the disconnect between the "explosive growth" narrative and the actual quarterly revenue trajectory. While the annual revenue jumped from $55.3M in 2024 to $175.1M in 2025, the quarterly data reveals a decelerating and volatile launch. Revenue grew from $28.5M in Q1 2025 to $39.5M in Q2, but then stalled at $49.5M in Q3 and $57.6M in Q4. The most recent quarter (Q2 2026) showed $74.3M, which is a strong sequential jump, but the prior quarter (Q1 2026) was only $58.3M. This suggests the "391% CAGR" is a statistical artifact of a tiny base, not a sustainable linear growth curve. More concerning is the net income trajectory: it improved from a catastrophic -$94.3M in Q1 2025 to -$17.6M in Q2 2026, but this improvement is driven by revenue scaling, not operational efficiency. The operating loss in 2025 was -$160M on $175M revenue, meaning the company loses $0.91 for every $1 of revenue at the operating level. The "pre-profit" label is an understatement; this is a company with a negative equity position of -$438.2M and a cash burn that outpaces its cash reserves.
The balance sheet is the critical failure point that the valuation models are glossing over. With $130M in cash and $209M in total debt, the net cash position is negative $79M. The operating cash flow for 2025 was -$166.8M. Even if we assume the Q2 2026 net loss of -$17.6M is the new steady state (which is optimistic given the seasonality and launch costs), the company is burning cash at a rate that will exhaust its $130M cash pile in less than two years, likely sooner if they need to service debt or fund further commercial expansion. The current ratio of 1.92 is misleading because it includes inventory and receivables that may not convert to cash quickly enough to cover the debt obligations. The "neutral market forces" signal is dangerously optimistic; this is a company facing an imminent liquidity crisis, not a neutral execution risk. The insider activity is also a red flag: the recent transactions are mostly awards and option exercises, not open-market purchases. The "G-Gift" of 28,000 shares in May 2026 is likely a compensation adjustment, not a confidence signal. There is no insider buying to offset the dilution risk.
The strongest case against my bearish read is the clinical differentiation of vonoprazan. The PHALANX trials show superior acid suppression compared to PPIs, and the GERD market is massive. If Phathom can capture even 5% of the US GERD market, the revenue potential is in the billions. The gross margin of 82.9% is healthy for a biotech, indicating that the product itself is profitable at the unit level. The problem is the SG&A and R&D overhead. If the company can scale revenue to $400M+ with the same gross margin, the operating leverage could flip the company to profitability quickly. The market is pricing in a "turnaround bet," and if the Q3 2026 revenue continues to grow at the Q2 2026 pace (27% QoQ), the cash burn could stabilize. However, this requires perfect execution and no competitive disruption from new PPIs or other PCABs. The risk/reward is skewed because the downside is bankruptcy or massive dilution, while the upside is just "profitability," which is already priced into the $7.74 share price given the 2.57x P/S ratio.
What would change my mind is a clear signal of cash flow breakeven or a non-dilutive financing event. If the next two quarters show operating cash flow turning positive, or if the company announces a strategic partnership that provides upfront cash and reduces R&D burden, the liquidity crisis would be mitigated. Additionally, if the revenue growth rate accelerates to over 40% QoQ, it would suggest that the initial launch hiccups are behind them and the product is gaining true market traction. Conversely, if the Q3 2026 revenue falls below $65M, or if the company announces a dilutive equity offering to raise cash, my bearish stance would be confirmed. The current price of $7.74 is not cheap for a company with negative equity and a cash burn that exceeds its cash reserves. It is a high-risk bet on a single product's commercial success, with no safety net.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Phathom is executing a real commercial launch: revenue went from $0 in 2023 to $9.9M in 2024 to $114M in 2025 to $239.7M TTM, with gross margins holding in the low-to-mid 80s (82.9% latest). Operating loss margin has compressed from -2549% to -17% as the top line scales against a largely fixed launch cost base — genuine operating leverage is showing. Net loss also improved sharply from -$330M to -$99M and FCF burn narrowed from -$275M to -$37M. That is the bull side of the ledger and it is real. The bear side: the company is still not self-funding, and the balance sheet is thin — $182.5M liquid cash against enough debt to leave only $17.9M net cash, which is why Altman Z sits at -5.15 in the distress zone. Runway math (19.8 quarters) is generous only because burn has just collapsed; a launch stumble or payer pushback would reset that quickly. SBC at 11.3% of revenue is heavy but tolerable given the ramp, and diluted share count has actually been broadly stable (~80M, -0.4% CAGR), so per-share value is not being shredded. Insider tape is entirely awards, tax withholdings, and gifts — no open-market buying to signal conviction, no selling to signal alarm. Durability depends on Voquezna's competitive position vs. entrenched PPIs and payer coverage, which the numbers alone cannot confirm.
Verify before trusting this (6)
- Debt structure: maturity, covenants, and any convertible terms behind the $165M gap between gross and net cash
- Voquezna payer coverage breadth and gross-to-net trajectory in 10-Q/10-K
- Inventory and receivables build driving the -19.1% accruals figure
- Competitive position vs. Takeda's vonoprazan rights and entrenched PPI generics
- Guidance or commentary on cash-flow breakeven timing
- Any royalty/financing obligations to Takeda or lenders that could re-accelerate cash outflows
The e2e synthesis is blunt: to justify today's price, Voquezna revenue has to roughly triple and the company has to reach profitability on a reasonable timeline. That is a demanding but not absurd bar for a first-in-class PCAB mid-launch, which is why I read the current $626M market cap as roughly a fair option-value on the ramp rather than a screaming discount. There is no cash-adjusted margin of safety here - the company still carries real debt against ongoing losses (flagged by the Quality lens as an Altman Z concern), so the equity value is essentially a bet on the launch curve, not on assets.
Verify before trusting this (4)
- Latest Voquezna quarterly TRx trajectory and net-price realization
- Cash runway and any covenant/refi terms on the debt stack
- Formulary/payer coverage wins and gross-to-net evolution
- Management guidance on breakeven timing and peak-sales framing
PHAT is a moderate-intensity turnaround story riding on VOQUEZNA's commercial ramp — the kind of single-product biotech where the tape trades the narrative, not the numbers. The story is neither cult nor collapsing: intensity and durability are moderate, meaning sentiment can swing sharply on each print. That was on display on 2026-07-30 when a 22.5% drop followed an otherwise strong beat, and again in April when a narrower loss still got sold. The market is punishing execution friction (prior-auth issues, opex) even when headline growth is triple digits — a classic sign the narrative is fragile and buyers demand cleaner proof. Macro-wise the risk-off tape (VIX 17.7, S&P off highs, 10y at 5%) is a headwind for pre-profit biotech in general, but PHAT's low 0.51 beta blunts the direct market pull. What matters more is that risk-off tapes compress multiples on story stocks with no earnings anchor, and PHAT is exactly that. Offsetting: momentum is still net positive on longer windows (+2,954bps over 3y, 110% recent), so the tape has not broken the uptrend — it has just introduced doubt. Net: mild headwind, not a rout.
Verify before trusting this (4)
- Next quarterly print — whether prior-auth friction is easing and script trajectory reaccelerates
- Any payer/formulary wins or losses that would validate or break the ramp narrative
- Whether biotech risk sentiment (XBI) stabilizes as the risk-off regime evolves
- Analyst target revisions post the July selloff — direction of tone matters more than the level
The relevant world is prescribing behavior and payer economics, not macro. Acid suppression is one of the largest and most thoroughly genericized prescription categories on earth, so every dollar PHAT adds is taken from a pennies-per-pill incumbent — that is why access, copay economics and specialist advocacy matter more than GDP or rates here. Two forces work for the company: real clinical differentiation in erosive-GERD healing and maintenance, and the fact that the installed base of PPI-refractory patients is enormous relative to current revenue. Two work against it: US payers are aggressively re-imposing step therapy on branded alternatives to cheap generics, and capital markets for pre-profit biotech are tight (sector in contraction, macro headwinds, 10y ~5%), which raises the cost of the promotional spend the ramp depends on. Net: the demand-side world is permissive for a differentiated GI brand; the financing-side world is not, and that asymmetry is the crux of the next 24 months.
Prediction unavailable. valuation-synthesis has no result for PHAT — the prediction needs its fair-value anchors.